Target intelligence / Profile preview

Ras protein activator like 1 (RASAL1)

Target
RASAL1
Molecular classification
Enzyme, GTPase-activating protein (GAP), Signal transduction modulator
01

Overview

Ras protein activator like 1 (RASAL1) is a member of the GAP1 family of GTPase-activating proteins that suppress RAS function by enhancing the intrinsic GTPase activity of RAS proteins, thus converting active RAS-GTP to the inactive RAS-GDP form. This crucial regulation prevents excessive cell proliferation and maintains normal cellular signaling. RASAL1 is highly expressed in endocrine tissues and is implicated in the negative regulation of the Ras-ERK/MAPK pathway. Loss or dysfunction of RASAL1 has been associated with increased Ras pathway activity and contributes to the development of various cancers and proliferative disorders.

Other names
RasGAP-activating-like protein 1RASAL1GAP1 family protein
02

Mechanism of action

For theoretical inhibitors: Inhibition or modulation of RASAL1 would affect Ras deactivation and downstream MAPK/ERK signaling. RASAL1 itself inactivates RAS by accelerating GTP hydrolysis, converting active RAS-GTP to inactive RAS-GDP.

03

Biological functions

Negative regulation of Ras signalingControl of cell proliferation and differentiationRegulation of dendrite formation in melanocytesModulation of the Ras-cyclic AMP pathway
04

Disease associations

Cancer (including melanoma, cutaneous malignant melanoma, and other tumors)Fibromatosis (ossifying fibroma)Disorders involving Ras/MAPK pathway dysregulation
05

Safety considerations

Modulation of RASAL1 could lead to dysregulated cell proliferation, increasing risk of tumorigenesis.Targeting RasGAPs may result in on-target toxicity due to their broad role in cellular growth control.
06

Interacting drugs

No FDA-approved drugs directly target RASAL1; RAS pathway inhibitors (like MEK or ERK inhibitors) are in clinical use, but these target downstream pathway components, not RASAL1 itself.
07

Biomarkers

No established clinical biomarkers specific for RASAL1; Ras/MAPK pathway alterations are used for patient selection in studies involving pathway inhibitors

Beyond the preview

Go deeper on Ras protein activator like 1 (RASAL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ras protein activator like 1 (RASAL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call